SiBone (NASDAQ:SIBN) Price Target Raised to $26.00

SiBone (NASDAQ:SIBN) had its price target raised by investment analysts at UBS Group from $25.00 to $26.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group‘s price objective suggests a potential upside of 12.44% from the company’s previous close.

Several other analysts have also weighed in on the company. Citigroup reaffirmed a “market outperform” rating on shares of SiBone in a research note on Tuesday. Needham & Company LLC decreased their target price on SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Tuesday. TD Cowen boosted their target price on SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, Truist Financial raised their price target on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

SiBone Price Performance

Shares of SIBN stock traded up $2.90 during trading hours on Tuesday, reaching $23.12. The company’s stock had a trading volume of 736,082 shares, compared to its average volume of 616,200. The firm’s 50 day simple moving average is $19.42 and its 200-day simple moving average is $16.45. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -68.66 and a beta of 0.66. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $22.95. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. The company had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. Sell-side analysts forecast that SiBone will post -0.40 earnings per share for the current year.

Insider Transactions at SiBone

In related news, SVP Michael A. Pisetsky sold 29,665 shares of the business’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $22.11, for a total transaction of $655,893.15. Following the sale, the senior vice president owned 164,444 shares in the company, valued at $3,635,856.84. The trade was a 15.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Laura Francis sold 51,884 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64. Following the sale, the chief executive officer owned 321,386 shares in the company, valued at $6,254,171.56. This represents a 13.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 238,371 shares of company stock valued at $4,738,916 over the last quarter. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On SiBone

Several large investors have recently bought and sold shares of the company. First Light Asset Management LLC grew its holdings in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC increased its stake in shares of SiBone by 97.6% in the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after buying an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY raised its holdings in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock valued at $14,228,000 after buying an additional 598,300 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after buying an additional 182,465 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after buying an additional 238,219 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

Key SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly loss and revenue beat expectations. SiBone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 analyst consensus, while revenue rose 14.5% year over year to $55.7 million, slightly ahead of the $55.3 million estimate. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Operating performance and cash generation improved. Adjusted EBITDA increased 32.4% to $3.0 million, operating cash flow jumped 154.4% to $5.9 million, and SiBone ended the quarter with $146.3 million in cash. These results strengthen the investment case despite continued GAAP losses. SI-BONE Reports Third-Quarter 2026 Results
• Positive Sentiment: Growth catalysts remain intact. U.S. procedure volume rose approximately 20%, the active physician base grew 16% to 1,770, and the company received FDA clearance for its iFuse Granite Onyx breakthrough device. New reimbursement rules could also increase hospital payments by as much as $50,000 for qualifying complex spinal-fusion procedures. SI-BONE Reports Third-Quarter 2026 Results
• Positive Sentiment: TD Cowen raised its price target. The firm lifted its target from $20 to $23 and maintained a “buy” rating, reinforcing bullish analyst sentiment as the stock approaches that revised objective. TD Cowen Analyst Rating
• Neutral Sentiment: Revenue guidance was reaffirmed. SiBone expects fiscal 2026 revenue of $231 million to $233 million, broadly in line with the $232.2 million consensus estimate. The outlook supports stability but does not represent a major forecast upgrade.
• Negative Sentiment: Insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for approximately $655,893, while Anshul Maheshwari sold 3,738 shares for $84,105. Both retained sizable positions, but the sales may modestly weigh on sentiment with SIBN near its 52-week high. Insider Sale Filing

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.